InvestSMART

Medical Developments International Limited (ASX:MVP)

ALERT: Price-sensitive ASX Announcement for MVP
Current share price for MVP : $0.405 -0.05 (-10.99%)+
Announcement
Release
19 Feb 2026 8:54AM
Price at Release
$0.455
Full Release
download
Summary
Medical Developments International Limited (MVP) presented its FY26 Half Year Results, emphasizing strong growth in its Pain Management segment driven by Penthrox®, a non-opioid analgesic, with volumes growing by 26% in Australian hospitals and underlying demand increasing by 10% in Europe. Despite a 10% decline in the Respiratory segment, MVP achieved positive operating cash flow of $0.3 million and improved its free cash flow by $1 million, maintaining a strong cash balance of $16.9 million. The company is focused on expanding Penthrox®'s reach, including finalizing approvals for a paediatric label in Europe. MVP's strategic objectives include enhancing commercial and medical investments, driving global market penetration, and achieving operational efficiencies, all while managing cost increases and maintaining profit margins.
Key Points
  • Penthrox® volume growth of 26% in Australian hospitals.
  • Underlying demand for Penthrox® in Europe up 10%.
  • MAGPIE paediatric study strengthens clinical evidence.
  • Paediatric label approvals in Europe progressing.
  • Health economic study shows cost savings with Penthrox®.
  • Operating cash flow improved by $1.0 million.
  • Strong balance sheet with $16.9 million cash as of December 2025.
  • Group revenue increased by 8% to $21.6 million.
  • Pain Management segment revenue up 18%.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.